Salomon Manier

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma

Iryna Dekhtiarenko, Jan Attig, Iva Lelios, Stephan Schmeing et autres

T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these challenges ask for new approaches …

ch, it, dk, fr, kr, gb, au (code pays fourni par la source)

IFM 2026 Recommendations for First-Line Treatment of Newly Diagnosed Multiple Myeloma

Aurore Perrot, Salomon Manier, Cyrille Hulin, Hélène Demarquette et autres

The treatment landscape of newly diagnosed multiple myeloma (NDMM) has changed considerably over the past five years. Anti-CD38-VRd quadruplets are now the standard of care for transplant-eligible patients and an important option for transplant-ineligible patients. This review presents unified, evidence-based first-line treatment …

fr (code pays fourni par la source)

Supportive Care in Multiple Myeloma: Evidence-Based Recommendations from the Intergroupe Francophone du Myélome (IFM)

Laurent Frenzel, Pascal Godmer, Alexis Talbot, Cécile Sonntag et autres

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Thierry Façon, Shaji Kumar, Robert Z. Orlowski, Nizar J. Bahlis et autres

In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report results on long-term OS and subsequent antimyeloma therapies from the MAIA final analysis. …

fr, us, ca, de, gb, nl, se, dk, au (code pays fourni par la source)

MM-770: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma Responding to Bridging Therapy: CARTITUDE-4 Cytogenetic Subgroup Analysis

Roberto Mina, Niels WCJ van de Donk, Cyrille Touzeau, Yaël C. Cohen et autres

us, nl, fr, il, de, es, jp, au, in (code pays fourni par la source)

POSTER: MM-770: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma Responding to Bridging Therapy: CARTITUDE-4 Cytogenetic Subgroup Analysis

Roberto Mina, Niels WCJ van de Donk, Cyrille Touzeau, Yaël C. Cohen et autres

us, nl, fr, il, de, es, jp, au, in (code pays fourni par la source)

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

Efstathios Kastritis, Shaji Kumar, S. Vincent Rajkumar, Wee Joo Chng et autres

Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence …

gr, us, sg, de, br, is, fr, es, ca, gb, kr, it (code pays fourni par la source)

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma

Benjamin Podvin, Holly Lee, Rémi Tilmont, Gauthier Decool et autres

[Figure: see text]

fr, ca, es (code pays fourni par la source)

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Aurore Perrot, Cyrille Touzeau, Stéphane Minvielle, Cyrille Hulin et autres

Multiple myeloma (MM) remains a heterogeneous disease with diverse molecular and cytogenetic profiles that influence treatment responses and long-term outcomes. The translocation t(11;14), which leads to overexpression of cyclin D1 (CCND1), is the most common primary translocation event in MM, affecting around …

fr (code pays fourni par la source)

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy

Titouan Cazaubiel, Cyrille Touzeau, Laure Vincent, Karim Belhadj et autres

fr, be (code pays fourni par la source)

Abstract 7298: Extracellular acidosis modulates calcium signaling and adaptive resistance mechanisms in acute myeloid leukemia

Eva Gez, Sofia Titah, Aurélie Guillemette, Céline Berthon et autres

Abstract Acute Myeloid Leukemia (AML) is a malignant hematological disease with a high relapse rate linked to multiple resistance mechanisms, including leukemic stem cells, apoptosis resistance, and efflux pump activation. Previous work in the host laboratory demonstrated that calcium signaling contributes to …

fr (code pays fourni par la source)

Aiolos and Eos drive distinct human TH17 functional states

Silvia Cerboni, Leila Mohammadnezhad, Komal Agrawal, Ramachandramouli Budida et autres

CD4+ T helper (TH)-17 cells play a pivotal role in mucosal immune defense and are implicated in autoimmune diseases and cancer. Although Th17 cell plasticity is well-studied in mice, the factors driving their transition between pro-inflammatory and immunomodulatory states in humans remain …

se, fr, us, gb, fi, es (code pays fourni par la source)